Cortellaro M, Boschetti C, Fassio G, Basagni M, Polli E E
Acta Haematol. 1979;61(2):68-74. doi: 10.1159/000207634.
Preliminary data obtained in the ambit of Anturan Reinfarction Italian Study (ARIS) show that, in postmyocardial infarction, reduced platelet survival time occurred in hyperbetalipoproteinemic patients treated with placebo, but not in the group of patients treated with sulfinpyrazone (interaction between treatment and lipemic level is at p approximately equal to 0.1). The sulfinpyrazone effect on platelet survival is probably related to the release reaction inhibition as suggested by our ex vivo results on platelet-bound 14C-serotonin release.
在意大利安替比林再梗死研究（ARIS）范围内获得的初步数据表明，在心肌梗死后，接受安慰剂治疗的高β脂蛋白血症患者血小板存活时间缩短，而接受磺吡酮治疗的患者组则未出现这种情况（治疗与血脂水平之间的相互作用p值约为0.1）。正如我们关于血小板结合的14C-血清素释放的体外实验结果所表明的，磺吡酮对血小板存活的影响可能与释放反应的抑制有关。
